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Background: CTLA4 blocking monoclonal antibodies provide a low frequency but durable tumor responses in
patients with metastatic melanoma, which led to the regulatory approval of ipilimumab based on two randomized
clinical trials with overall survival advantage. The similarly fully human anti-CTLA4 antibody tremelimumab had been
developed in the clinic at a fixed rate infusion, resulting in very prolonged infusion times. A new formulation of
tremelimumab allowed testing a shorter infusion time.
Methods: A phase 1 multi-center study to establish the safety and tolerability of administering tremelimumab as a
1-hour infusion to patients with metastatic melanoma. Secondary endpoints included pharmacokinetic and clinical
effects of tremelimumab.
Results: No grade 3 or greater infusion-related adverse events or other adverse events preventing the
administration of the full tremelimumab dose were noted in 44 treated patients. The overall side effect profile was
consistent with prior experiences with anti-CTLA4 antibodies. Objective tumor responses were noted in 11% of
evaluable patients with metastatic melanoma, which is also consistent with the prior experience with CTLA4
antagonistic antibodies.
Conclusions: This study did not identify any safety concerns when tremelimumab was administered as a 1-hour
infusion. These data support further clinical testing of the 1-hour infusion of tremelimumab. (Clinical trial
registration number NCT00585000).
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The cytotoxic T lymphocyte-associated antigen 4
(CTLA4) is a co-inhibitory receptor transiently expressed
on the surface of activated T lymphocytes and constitu-
tively expressed by T regulatory (Treg) cells [1]. It has a
dominant immune-dampening effect on self-reactive T
cells. CTLA4 has become a validated target for therapy
in patients with metastatic melanoma based on the sur-
vival advantage in two phase 3 clinical trials using the* Correspondence: aribas@mednet.ucla.edu
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reproduction in any medium, provided the orCTLA4 blocking fully human IgG1 antibody ipilimumab
(formerly MDX010) [2,3]. Tremelimumab (also known as
CP-675,206) is a fully human monoclonal antibody of
IgG2 subtype that also binds and antagonizes the func-
tion of CTLA4. The antagonistic effect of tremelimumab
on CTLA4 enhances human T cell activation as demon-
strated using in vitro assays [4]. This antibody has been
in clinical testing for the treatment of malignancies since
2002 [5], and continues in clinical development as single
agent and in combination in several cancer indications.
Prior clinical trials demonstrated that tremelimumab
induces durable tumor regressions, sometimes lasting
beyond 5 years, in approximately 10% of patients with
metastatic melanoma [5-7]. These tumor responses aretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lymphocytes (CTLs) as demonstrated in patient-derived
tumor biopsies [8,9]. The most common toxicities with
tremelimumab administration are skin rash and diarrhea/
colitis, with a few percent of patients experiencing
endocrine abnormalities such as thyroiditis and hypo-
physitis. Grade 3/4 toxicities occur in about 15-20% of
patients. A randomized phase 2 clinical trial compared
the regimens of 10 mg/kg monthly and 15 mg/kg every
90 days. This study suggested that the 15 mg/kg every
three month schedule was preferred based on lower
toxicities while maintaining tumor response rates and
having similar survival [6]. This dosing regimen has
been tested in two pivotal clinical trials in patients with
advanced melanoma. A phase 2 single arm trial in
patients (n=251) with previously treated metastatic mel-
anoma demonstrated a tumor response rate of 9.1% per
investigator assessment and 6.6% per central radiological
review, and thus failed to demonstrate that the response
rate exceeds 10% [10]. In a phase 3 randomized clinical
trial, the median overall survival was 12.6 months in
the tremelimumab arm compared to 10.7 months in
the chemotherapy arm, but the difference in overall
survival was not statistically significant. A major con-
tributing factor was a higher than expected use of ipili-
mumab in patients randomized to the chemotherapy
control arm. Response rates in the two arms were simi-
lar, but duration of response was significantly longer in
the tremelimumab arm [7], consistent with the notion
that this agent provides durable tumor responses in a
subset of patients as its major clinical benefit.
Prior to this study, tremelimumab had been adminis-
tered to over 800 subjects at a fixed rate of 100 mL/hour,
resulting in infusion times between 1.0 and 5 hours.
Since tremelimumab is a fully human monoclonal anti-
body that did not demonstrate evidence of infusion-
related cytokine release in prior clinical testing [5,6,10],,
nor there were reports of infusion reactions with ipili-
mumab [2,3,11], it was reasoned that a shorter infusion
time may be safe. A new formulation of tremelimumab
allowed a lower fluid volume for administration, facilita-
ting a shorter infusion time. The current study was
conducted to establish the safety and tolerability of
administering tremelimumab as a 1-hour infusion, which
may increase patient convenience in further clinical test-
ing of this antibody.
Materials and methods
Study design and conduct
This open-label, single arm multi-institutional study was
planned for approximately 110 subjects. The original
study protocol stated that enrollment should terminate
if 3 or more subjects experienced tremelimumab-related
adverse events (AEs) during or immediately after theinfusion. All subjects signed a written informed consent
approved by the Institutional Review Board (IRB) at each
study site. The study was conducted in accordance
with local regulations, the guidelines for Good Clinical
Practice (GCP), and the principles of the current version
of the Declaration of Helsinki. The study opened to ac-
crual at 7 US centers, was sponsored by Pfizer Inc. (New
York, NY), and had the clinical trial registration number
NCT00585000.
Study objectives and assessments
The primary objective was to assess the safety and
tolerability of tremelimumab at 15 mg/kg as a one-
hour infusion. Secondary objectives included charac-
terizing the pharmacokinetics (PK), monitoring for
human anti-human antibody (HAHA), and assessing
anti-tumor activity by best overall tumor response
rate using Response Evaluation Criteria in Solid
Tumors (RECIST) criteria.
Study population
Eligible subjects were aged 18 years or older with histolo-
gically confirmed stage III or IV melanoma considered to
be surgically incurable, with evidence of at least 1 meas-
urable or non-measurable lesion according to RECIST
criteria, with an Eastern Cooperative Oncology Group
(ECOG) performance status of 1 or lower, with adequate
bone marrow, hepatic, and renal function. Subjects were
excluded if they had had a potential requirement for sys-
temic corticosteroids or concurrent immunosuppressive
drugs, had an inherited or acquired immunodeficiency,
had a history of chronic autoimmune disease, inflamma-
tory bowel disease, active or chronic viral hepatitis, uve-
itis or melanoma-associated retinopathy. Patients with a
history of brain metastases were eligible if they had been
adequately treated with surgery or stereotactic radio-
surgery and were stable for at least 3 months prior to
enrollment.
Tremelimumab administrations
Subjects received an intravenous administration of tre-
melimumab at a dose of 15 mg/kg via infusion pump as
a 1-hour infusion, repeated every 90 days up to a max-
imum of 4 doses.
Safety, efficacy, and pharmacokinetic evaluations
Adverse events (AEs) were graded according to the
National Cancer Institute Common Terminology Criteria
for Adverse Events (CTCAE Version 3.0). Radiologic and
clinical evaluations were performed within 28 days prior
to dosing and within 10 days prior to the planned start of
each 90-day cycle. Blood samples for pharmacokinetic
analyses were obtained just prior to administration of
tremelimumab for every treatment cycle (cycles 1–4), with
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after the end of infusion, on days 2, 3, 8, 15, 30, 45, 60 and
75 with ± 2 days to accommodate scheduling problems) to
fully characterize the pharmacokinetic profile of the infu-
sion regimen.Table 1 Demographic characteristics

















Current disease stagePharmacokinetic analysis
Plasma samples were analyzed for tremelimumab con-
centrations using a validated, sensitive and specific
enzyme-linked immunosorbent assay (ELISA) (ALTA
Analytical Laboratory, San Diego, CA) as previously
described [5,6]. The PK assay underwent formal meth-
odology optimization, with linear calibration of stand-
ard responses over the range of 7.8 to 250 ng/mL using
a 5 parameter curve-fit weighted model. Those samples
with concentrations above the upper limits of quantifi-
cation were adequately diluted into the calibration
range. The lower limit of quantification (LLOQ) for
tremelimumab was 7.8 ng/mL. Assay precision, expre-
ssed as the between-day coefficients of variation
(CV [%]) of the mean estimated concentrations of
quality control samples ranged from 9.34% to 11.5% for low
(25.0 ng/mL), medium (50.0 ng/mL), high (100 ng/mL),
and diluted (25.0 ng/mL) concentrations. Samples below
the LLOQ were set to 0 ng/mL for analysis. Nominal
sample collection times were used for the PK analysis.
The concentration-time data were analyzed by non-
compartmental analysis. Parameters of tremelimumab dis-
position included clearance (CL), volume of distribution at
steady state (Vss), and terminal phase half-life (t1/2). Para-
meters of tremelimumab exposure included plasma con-
centration of tremelimumab one hour after the end of
infusion (Cmax) and area under the concentration curve
from time zero to infinity (AUCinf). Comparison PK data is
presented from study A3671008, a pivotal phase II study in
which tremelimumab was administered as a 5-hour infu-
sion (11).IIIc 1 (2.3)
IV M1a 9 (20.5)
IV M1b 11 (25.0)
IV M1c 23 (52.3)
Measurable disease and adequate baseline assessment
Yes 37 (84.1)
No 4 (9.1)
Not reported 3 (6.8)






ECOG = Eastern Co-operative Oncology GroupHuman anti-human antibody (HAHA) assessment
A blood specimen for HAHA was obtained just prior to
administration of tremelimumab every treatment cycle.
In cycle 1, blood specimens were also obtained on days
30 and 60. HAHA samples were analyzed for the pres-
ence or absence of anti-tremelimumab antibodies fol-
lowing a tiered approach using screening, confirmation
and titer/quantitation as previously described [5]. The
semi-quantitative ELISA with electrochemiluminescence
detection (ECL) included a positive control (cynomolgus
anti-CP675,206 antibody sera) and negative control
(pooled normal human plasma). Assay precision, ex-
pressed as the between-day CV%, was less than 16.7%
for the positive control (used to calculate assay cut
point) and 13.1% for the negative control.Statistical analysis
The primary goal of the study was to demonstrate that
the infusion-related reaction rate for one-hour infusion
did not exceed 5% with a one-sided exact binomial test
at 10% significance level (alpha=0.10). 110 subjects
would provide 90% power to reject the null hypothesis
(infusion-related reaction rate ≥5%) when the true
infusion-related reaction rate did not exceed 1%.
Results and discussion
Study subjects and treatment administration
Forty-nine subjects were enrolled to this protocol be-
tween December 2007 and July 2008, and 44 subjects
received at least one infusion of tremelimumab. Enroll-
ment to this study was stopped early by the sponsor.
Forty-one subjects were included in the analysis of





During infusional + 1 hour 5 (14%) 0
Fatigue 22 (50%) 2 (4.5%)
Diarrhea 21 (48%) 3 (7%)
Rash 18 (41%) 0
Decreased appetite 16 (36%) 0
Nausea/Vomiting 15 (34%) 0
Pruritus 12 (27%) 0
Dehydration 2 (4.5%) 2 (4.5%)
Thrombocytopenia 1 (2%) 1 (2%)
This table includes all events that occurred in greater than 10% of patients
(any grade), or that occurred in at least 2 patients at grade ≥3, or that
occurred in any patient at grade 4.
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laboratory data recorded after day 0 or day 1 (two sub-
jects progressed rapidly and one withdrew consent).
Demographic characteristics are summarized in Table 1.
Seventy percent were male and 70% were older than
65 years. The mean duration since first diagnosis of ma-
lignant melanoma was 5.3 years (range 0.1 to 20.4 years).
Over half of the patients had stage IV M1c disease and
approximately 80% had previously received at least 1
prior systemic therapy for advanced melanoma. Twenty-
nine (65.9%) treated patients received a single dose; 6
(13.6%) received a total of 2 doses; 3 (6.8%) received a
total of 3 doses, and six (14%) subjects completed
4 cycles of treatment. Four (9.1%) subjects had at least
one dose delay and three (7%) had the therapy discontin-
ued due to an adverse event beyond the time of infusion
(one each due to autoimmune thrombocytopenia, aller-







Figure 1 PET scans on patient 10121002 in this trial. The top row inclu
and the bottom row includes imaging scans off therapy. The patient had m
scan performed 3 months later and has continued on a durable response fSafety results
No grade 3 or greater infusion-related AEs, or other AEs
preventing the full tremelimumab dose from being
administered were reported. Although under-powered
due to the early stopping of the clinical trial, the p-value
for the primary hypothesis test was 0.099 (<0.10). Des-
pite having enrolled less patients than was initially
planned, the null hypothesis should be rejected with the
risk of <0.0001 (type II error) of having reached a wrong
conclusion that the infusion-related reaction rate did not
exceed 5%. During study drug infusion, 5 (11%) subjects
experienced 7 AEs (1 AE of diarrhea, abdominal disten-
sion, urticaria, flushing, hypertension, and 2 AEs of
hypotension); all of these AEs were grade 1 or 2 and oc-
curred during cycle 1. No SAEs occurred during infu-
sion. There were no permanent discontinuations due to
AEs occurring during study drug infusion; however, 1
subject temporarily discontinued study drug due to AEs
of diarrhea and urticaria. Overall, 42 (95%) subjects
experienced at least one AE, and 17 (39%) subjects at
least 1 SAE. Three (7%) subjects permanently discontin-
ued the study due to AEs. The most commonly reported
AEs (Table 2) were fatigue and diarrhea. The most com-
mon grade 3 AEs were diarrhea (three subjects), and fa-
tigue and dehydration (each two subjects). The only
reported grade 4 AE was autoimmune thrombocytopenia
(one subject). All of these side effects were consistent
with the prior experience with anti-CTLA4 antibodies
like tremelimumab and ipilimumab [2,3,5,6,10-13].
Tumor responses
Results of antitumor activity in this study were concord-
ant with the prior results of administering tremelimu-
mab to patients with advanced melanoma [13]. Among+6 +11 +21 months
+34 +37 +42  months
des imaging scans performed while the patient was on active therapy,
ultiple FDG positive metastases at baseline that responded by the PET
or over 3 years.




Complete response (CR) 0
Partial response (PR) 4 (11.1)
Stable for 10 weeks/no response 7 (19.4)
Objective progression 19 (52.8)
Indeterminate 6 (16.7)
Table 4 Summary of tremelimumab pharmacokinetic
parameter values following a 1-hour intravenous infusion
in comparison with those following a 5 -hour intravenous
infusion in A3671008 Study






(μg/mL) (days) (μg/mL) (days)
N 42 32 32 150 150 150
Mean 322 104500 19.6 329 112719 19.2
SD 62 32400 5.7 112 40933 5.9
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complete responses and four partial responses (example
in Figure 1), for an objective response rate of 11.1%
(95% CI: [3.1%, 26.1%]) as evaluated based on the central
analysis of tumor responses (Table 3). In addition, one
patient had a durable partial response (over 2 years and
continuing in maintained response) after an initial
period of tumor progression, and another patient has
remained disease-free for 2+ years after surgical resec-
tion of nodal metastases that were stable in size after
starting on tremelimumab.
Pharmacokinetic analysis
Figure 2 provides the plasma concentration over time of
tremelimumab in the 42 patients who received the 1-hour
infusion in study A3671022 compared to historical data
from 191 patients who received the 5-hour infusion of
tremelimumab in study A3671008. Tremelimumab PK






























Figure 2 Median tremelimumab concentration-time profiles following
The graph is in semi-logarithmic scale, with the 1-hour infusion data in 42
compared to the data from the A3671008 study where 191 patients receiv
discontinuous line and open squares.were similar (Table 4). The mean (standard deviation
[SD]) AUCinf after the first dose of 1-hour intravenous in-
fusion of 15 mg/kg tremelimumab was 104,500 (SD
32,400) μg*hr/mL. The mean (SD) Cmax was 322 (SD 62)
μg/mL and mean t1/2 was 470 hours (19.6 days). No sub-
ject had measurable HAHA suggesting minimal immuno-
genicity of tremelimumab after multiple 1-hour
intravenous infusions. Taken together, these data indicate
that the shorter infusion time did not alter the PK of tre-
melimumab, since the PK parameters are similar to those
after a 5-hour infusion of tremelimumab [5,14].
Conclusions
This study was conducted to establish the safety and tol-
erability of administering tremelimumab as a one-hour
infusion. The use of a shorter infusion is of importance
to patient convenience. The main finding of this study is




a 1-hour intravenous infusion compared to the 5 hour infusion.
patients from study A3671022 in solid line and filled diamonds,
ed tremelimumab with infusion times of 5–7 hours presented with a
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administered, were reported during the infusion period
in any of the study subjects. The one-hour infusion
safety and tolerability profile of tremelimumab was con-
sistent with that observed to date in other studies with
longer infusion times of this antibody. Therefore, we
conclude that the one-hour infusion of tremelimumab is
suitable for further clinical testing.
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